Clinical Trial Update: A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of larotrectinib in pediatric tumors with NTRK gene fusions; the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

Sponsor: Bayer | Conditions: Solid Tumors Harboring NTRK Fusion | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING